UB Paderborn / Katalog / Suche / in CDI

Es ist ein Fehler in der Kommunikation mit einem externen System aufgetreten. Bitte versuchen Sie Ihre letzte Aktion erneut. Sollte der Fehler bestehen bleiben, setzen Sie sich bitte mit dem Informationszentrum der Bibliothek in Verbindung oder versuchen Sie es später erneut.

1 – 25 von 364

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Peroxisome Proliferator-Activated Receptors α and γ are Linked with Alcohol Consumption in Mice and Withdrawal and Dependence in Humans

Alcoholism, clinical and experimental research, 2015-01, Vol.39 (1), p.136-145

2015

Volltextzugriff (PDF)

Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial

Journal of clinical lipidology, 2018-01, Vol.12 (1), p.173-184

2018

Volltextzugriff (PDF)

Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial

Atherosclerosis, 2016-06, Vol.249, p.36-43

2016

Volltextzugriff (PDF)

Fibrates for secondary prevention of cardiovascular disease and stroke

Cochrane database of systematic reviews, 2015-10, Vol.2018 (10), p.CD009580

2015

Volltextzugriff (PDF)

Fenofibrate Improves Liver Function and Reduces the Toxicity of the Bile Acid Pool in Patients With Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Who Are Partial Responders to Ursodiol

Clinical pharmacology and therapeutics, 2020-12, Vol.108 (6), p.1213-1223

2020

Volltextzugriff (PDF)

Outcomes of Combined Cardiovascular Risk Factor Management Strategies in Type 2 Diabetes: The ACCORD Randomized Trial

Diabetes care, 2014-06, Vol.37 (6), p.1721-1728

2014

Volltextzugriff (PDF)

Rationale for an adjunctive therapy with fenofibrate in pharmacoresistant nocturnal frontal lobe epilepsy

Epilepsia (Copenhagen), 2017-10, Vol.58 (10), p.1762-1770

2017

Volltextzugriff (PDF)

Factors associated with fragility fractures in type 2 diabetes: An analysis of the randomised controlled Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study

Diabetes/metabolism research and reviews, 2023-07, Vol.39 (5), p.e3631-n/a

2023

Volltextzugriff (PDF)

Fenofibrate increases circulating haematopoietic stem cells in people with diabetic retinopathy: a randomised, placebo-controlled trial

Diabetologia, 2021-10, Vol.64 (10), p.2334-2344

2021

Volltextzugriff (PDF)

Fenofibrate increases the amount of sulfatide which seems beneficial against Covid-19

Medical hypotheses, 2020-10, Vol.143, p.110127-110127, Article 110127

Buschard, Karsten

2020

Volltextzugriff (PDF)

Comparison of fenofibrate and pioglitazone effects on patients with nonalcoholic fatty liver disease

European journal of gastroenterology & hepatology, 2017-12, Vol.29 (12), p.1385-1388

2017

Volltextzugriff (PDF)

Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: French-Spanish experience

Clinics and research in hepatology and gastroenterology, 2018-12, Vol.42 (6), p.521-528

2018

Volltextzugriff (PDF)

Long-Term Effects of Intensive Glycemic and Blood Pressure Control and Fenofibrate Use on Kidney Outcomes

Clinical journal of the American Society of Nephrology, 2018-11, Vol.13 (11), p.1693-1702

2018

Volltextzugriff (PDF)

Optimised plasma sample preparation and LC‐MS analysis to support large‐scale proteomic analysis of clinical trial specimens: Application to the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial

Proteomics. Clinical applications, 2023-05, Vol.17 (3), p.e2200106-n/a

2023

Volltextzugriff (PDF)

Extended-Release Niacin Versus Fenofibrate in HIV-Infected Participants With Low High-Density Lipoprotein Cholesterol: Effects on Endothelial Function, Lipoproteins, and Inflammation

Clinical infectious diseases, 2015-09, Vol.61 (5), p.840-849

2015

Volltextzugriff (PDF)

Fenofibrate to prevent amputation and reduce vascular complications in patients with diabetes: FENO-PREVENT

Cardiovascular diabetology, 2024-09, Vol.23 (1), p.329-9, Article 329

2024

Volltextzugriff (PDF)

Uric acid predicts long‐term cardiovascular risk in type 2 diabetes but does not mediate the benefits of fenofibrate: The FIELD study

Diabetes, obesity & metabolism, 2020-08, Vol.22 (8), p.1388-1396

2020

Volltextzugriff (PDF)

The impact of vitamin D status on cardiometabolic effects of fenofibrate in women with atherogenic dyslipidemia

Clinical and experimental pharmacology & physiology, 2021-02, Vol.48 (2), p.186-194

2021

Volltextzugriff (PDF)

Heparin and insulin in the management of hypertriglyceridemia-associated pancreatitis: case series and literature review

Archives of Endocrinology and Metabolism, 2017-03, Vol.61 (2), p.198-201

2017

Volltextzugriff (PDF)

Alterations in plasma triglycerides and ceramides: links with cardiac function in humans with type 2 diabetes

Journal of lipid research, 2020-07, Vol.61 (7), p.1065-1074

2020

Volltextzugriff (PDF)

Effect of Fenofibrate on Progression of Diabetic Retinopathy

NEJM evidence, 2024-08, Vol.3 (8), p.EVIDoa2400179

2024

Volltextzugriff (PDF)

Effect of Fenofibrate and Niacin on Intrahepatic Triglyceride Content, Very Low-Density Lipoprotein Kinetics, and Insulin Action in Obese Subjects with Nonalcoholic Fatty Liver Disease

The journal of clinical endocrinology and metabolism, 2010-06, Vol.95 (6), p.2727-2735

2010

Volltextzugriff (PDF)

Relationship of low molecular weight fluorophore levels with clinical factors and fenofibrate effects in adults with type 2 diabetes

Scientific reports, 2021-09, Vol.11 (1), p.18708-18708, Article 18708

2021

Volltextzugriff (PDF)

Efficacy and safety of coenzyme A versus fenofibrate in patients with hyperlipidemia: a multicenter, double-blind, double-mimic, randomized clinical trial

Current medical research and opinion, 2020-06, Vol.36 (6), p.941-945

2020

Volltextzugriff (PDF)

Efficacy and safety of fenofibrate add-on therapy for patients with primary biliary cholangitis and a suboptimal response to UDCA

Revista española de enfermedades digestivas, 2018-09, Vol.110 (9), p.557-563

2018

Volltextzugriff (PDF)

1 – 25 von 364

Suche als RSS-Feed

Aktive Filter

ThemaAdult

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(329)
Mit Volltextzugriff
(257)

Publikationsform

Artikel
(364)

Sprache

10 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Humans
(364)
Fenofibrate - Therapeutic Use
(344)
Male
(322)
Middle Aged
(312)
Female
(292)
Science & Technology
(263)
Life Sciences & Biomedicine
(260)
Hypolipidemic Agents - Therapeutic Use
(246)
Aged
(198)
Fenofibrate
(147)
Biological And Medical Sciences
(133)
Medical Sciences
(130)
Triglycerides - Blood
(113)
Pharmacology. Drug Treatments
(85)
Treatment Outcome
(81)
Hyperlipidemias - Drug Therapy
(80)
Cholesterol - Blood
(73)
Drug Therapy, Combination
(67)
Cardiovascular System & Cardiology
(65)

14 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Peroxisome Proliferator-Activated Receptors α and γ are Linked with Alcohol Consumption in Mice and Withdrawal and Dependence in Humans

Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial

Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial

Fibrates for secondary prevention of cardiovascular disease and stroke

Fenofibrate Improves Liver Function and Reduces the Toxicity of the Bile Acid Pool in Patients With Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Who Are Partial Responders to Ursodiol

Outcomes of Combined Cardiovascular Risk Factor Management Strategies in Type 2 Diabetes: The ACCORD Randomized Trial

Rationale for an adjunctive therapy with fenofibrate in pharmacoresistant nocturnal frontal lobe epilepsy

Factors associated with fragility fractures in type 2 diabetes: An analysis of the randomised controlled Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study

Fenofibrate increases circulating haematopoietic stem cells in people with diabetic retinopathy: a randomised, placebo-controlled trial

Fenofibrate increases the amount of sulfatide which seems beneficial against Covid-19

Comparison of fenofibrate and pioglitazone effects on patients with nonalcoholic fatty liver disease

Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: French-Spanish experience

Long-Term Effects of Intensive Glycemic and Blood Pressure Control and Fenofibrate Use on Kidney Outcomes

Optimised plasma sample preparation and LC‐MS analysis to support large‐scale proteomic analysis of clinical trial specimens: Application to the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial

Extended-Release Niacin Versus Fenofibrate in HIV-Infected Participants With Low High-Density Lipoprotein Cholesterol: Effects on Endothelial Function, Lipoproteins, and Inflammation

Fenofibrate to prevent amputation and reduce vascular complications in patients with diabetes: FENO-PREVENT

Uric acid predicts long‐term cardiovascular risk in type 2 diabetes but does not mediate the benefits of fenofibrate: The FIELD study

The impact of vitamin D status on cardiometabolic effects of fenofibrate in women with atherogenic dyslipidemia

Heparin and insulin in the management of hypertriglyceridemia-associated pancreatitis: case series and literature review

Alterations in plasma triglycerides and ceramides: links with cardiac function in humans with type 2 diabetes

Effect of Fenofibrate on Progression of Diabetic Retinopathy

Effect of Fenofibrate and Niacin on Intrahepatic Triglyceride Content, Very Low-Density Lipoprotein Kinetics, and Insulin Action in Obese Subjects with Nonalcoholic Fatty Liver Disease

Relationship of low molecular weight fluorophore levels with clinical factors and fenofibrate effects in adults with type 2 diabetes

Efficacy and safety of coenzyme A versus fenofibrate in patients with hyperlipidemia: a multicenter, double-blind, double-mimic, randomized clinical trial

Efficacy and safety of fenofibrate add-on therapy for patients with primary biliary cholangitis and a suboptimal response to UDCA

Aktive Filter

Suchergebnisse filtern